Literature DB >> 7876546

Involvement of IFN-gamma in Bacillus Calmette-Guérin-induced but not in tumor-induced sensitization to TNF-induced lethality.

A Cauwels1, P Brouckaert, J Grooten, S Huang, M Aguet, W Fiers.   

Abstract

In healthy mice, murine (m) TNF is fairly lethal, whereas human (h) TNF (a selective murine TNF-R55 agonist) is rather harmless. However, we and others observed that mice suffering from a bacterial infection, such as Bacillus Calmette-Guérin (BCG), or bearing i.m. some types of tumor, develop a hypersensitivity to the IL-6-inducing and lethal properties of hTNF. This is a cardinal problem as it severely limits the potential use of hTNF-R55-specific agonists for systemic treatment of human cancer. Using mice carrying a targeted disruption in the gene encoding the IFN-gamma receptor (IFN-gamma Ro/o), we here report that endogenous IFN-gamma plays a crucial role in the development of TNF hypersensitivity during BCG infection. Indeed, both the lethality and the IL-6 induced by hTNF were drastically reduced in IFN-gamma Ro/o mice as compared with control mice. These results demonstrate that the enhancement of TNF effects is at least an equally important mechanism by which IFN-gamma contributes to BCG-induced hypersensitivity as the previously described augmentation of TNF production. Experiments in athymic nude mice, either depleted of NK cells or not, revealed that the latter cell population is an important source of the sensitizing IFN-gamma during BCG infection. In contrast, IFN-gamma Ro/o mice were as susceptible as control mice to the sensitizing effects of tumors. mTNF, which interacts with both mTNF-R55 and mTNF-R75 and causes lethality on its own, is as toxic in IFN-gamma Ro/o mice as in wt control mice; this means that TNF-induced IFN-gamma does not play a role in mTNF-induced lethality.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876546

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations.

Authors:  S Hayley; K Brebner; S Lacosta; Z Merali; H Anisman
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

2.  Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium.

Authors:  Filip Van Hauwermeiren; Marietta Armaka; Niki Karagianni; Ksanthi Kranidioti; Roosmarijn E Vandenbroucke; Sonja Loges; Maarten Van Roy; Jan Staelens; Leen Puimège; Ajay Palagani; Wim Vanden Berghe; Panayiotis Victoratos; Peter Carmeliet; Claude Libert; George Kollias
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

3.  Immune-mediated ECM depletion improves tumour perfusion and payload delivery.

Authors:  Yen Ling Yeow; Venkata Ramana Kotamraju; Xiao Wang; Meenu Chopra; Nasibah Azme; Jiansha Wu; Tobias D Schoep; Derek S Delaney; Kirk Feindel; Ji Li; Kelsey M Kennedy; Wes M Allen; Brendan F Kennedy; Irma Larma; David D Sampson; Lisa M Mahakian; Brett Z Fite; Hua Zhang; Tomas Friman; Aman P Mann; Farah A Aziz; M Priyanthi Kumarasinghe; Mikael Johansson; Hooi C Ee; George Yeoh; Lingjun Mou; Katherine W Ferrara; Hector Billiran; Ruth Ganss; Erkki Ruoslahti; Juliana Hamzah
Journal:  EMBO Mol Med       Date:  2019-11-11       Impact factor: 12.137

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.